President and CEO
Chao Xingjuan (Xingjuan “Jane” Chao, Ph.D.) is a Person and serves as President, Chief Executive Officer, and co‑founder of Ceribell, Inc. (CBLL), a medical technology company focused on AI‑enabled brain monitoring for critically ill patients.[[1]](https://simplywall.st/stocks/us/healthcare/nasdaq-cbll/ceribell/management)[[2]](https://www.quiverquant.com/news/Ceribell,+Inc.+($CBLL)+President,+CEO,+and+Co-Founder+2025+Pay+Revealed)[[3]](https://www.fogartyinnovation.org/an-afternoon-with-ceribells-jane-chao/)[[5]](https://ceribell.com/about-us/leadership-team/) She has led Ceribell as CEO since its early concept stage in 2015, guiding the organization through FDA clearance of its rapid EEG system, commercial launch, and a roughly $200 million IPO, while remaining on the company’s board of directors.[[1]](https://simplywall.st/stocks/us/healthcare/nasdaq-cbll/ceribell/management)[[3]](https://www.fogartyinnovation.org/an-afternoon-with-ceribells-jane-chao/)[[4]](https://www.youtube.com/watch?v=X6DqSgNGXZc)[[5]](https://ceribell.com/about-us/leadership-team/) In 2025, Chao received estimated total compensation of about $4.57 million as Ceribell’s President, CEO, and Co‑Founder and was an active corporate insider, executing multiple sales of CBLL shares over the prior six months.[[1]](https://simplywall.st/stocks/us/healthcare/nasdaq-cbll/ceribell/management)[[2]](https://www.quiverquant.com/news/Ceribell,+Inc.+($CBLL)+President,+CEO,+and+Co-Founder+2025+Pay+Revealed)
Born in a small city in China, Chao was the first in her family to attend high school and college and later studied at Peking University before earning a Ph.D. in biophysics from Cornell University.[[3]](https://www.fogartyinnovation.org/an-afternoon-with-ceribells-jane-chao/)[[4]](https://www.youtube.com/watch?v=X6DqSgNGXZc) Her career began in management consulting at McKinsey & Company, followed by senior roles in the healthcare industry, including Senior Strategy Manager at Novartis and Principal Manager of Portfolio Management Strategy at Genentech, where she built expertise in portfolio and commercial strategy.[[3]](https://www.fogartyinnovation.org/an-afternoon-with-ceribells-jane-chao/)[[4]](https://www.youtube.com/watch?v=X6DqSgNGXZc) Drawing on this scientific and strategic background, Chao co‑founded Ceribell with two Stanford professors and has since been recognized for leading the development and commercialization of an FDA‑cleared, AI‑driven brain monitoring platform that is helping to change the standard of care for patients with serious neurological conditions.[[3]](https://www.fogartyinnovation.org/an-afternoon-with-ceribells-jane-chao/)[[4]](https://www.youtube.com/watch?v=X6DqSgNGXZc)[[5]](https://ceribell.com/about-us/leadership-team/)
View full insider profile →
Discussion